Elite in Polymyalgia Rheumatica

Dewi Guellec

CHU De Brest
Brest, FR 
Elite in Polymyalgia Rheumatica
CHU De Brest
Brest, FR 
OverviewLocationsClinical Research

Overview

Dewi Guellec practices in Brest, France. Ms. Guellec is rated as an Elite expert by MediFind in the treatment of Polymyalgia Rheumatica. Her top areas of expertise are Polymyalgia Rheumatica, Rhizomelic Pseudopolyarthritis, Whipple Disease, Actinomycosis, and Awake Craniotomy.

Her clinical research consists of co-authoring 52 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 11 articles in the study of Polymyalgia Rheumatica.

Gender
Female

Locations

CHU de Brest
Brest, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 18, 2024
Intervention Type: Drug, Biological
Study Drugs: Secukinumab, TNF blocker, Blood specimen
Study Phase: Phase 4
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: ABX464, Methotrexate
Study Phase: Phase 2
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
View 2 Less Clinical Trials

52 Total Publications

Usefulness of 18F-FDG PET-CT in detecting subclinical arteritis and cancer associated with polymyalgia rheumatica.
Usefulness of 18F-FDG PET-CT in detecting subclinical arteritis and cancer associated with polymyalgia rheumatica.
Journal: Joint bone spine
Published: February 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Guellec's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 10 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile